Abstract
We are conducting an open-label multicentre phase II study to evaluate the efficacy and safety of the combination therapy of XELOX and bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer. The primary endpoint of the study is progression-free survival. The secondary endpoints are the toxicity, overall response rate, time to treatment failure and overall survival. Thirty-five patients are required for the study.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Capecitabine
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Disease Progression
-
Disease-Free Survival
-
Drug Administration Schedule
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Staging
-
Oxaloacetates
-
Patient Selection
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Oxaloacetates
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
Fluorouracil